Latest Conference Articles

Women who had contralateral prophylactic mastectomy reported similar breast satisfaction and quality of life, cancer-related distress and anxiety and depression scores, compared with those who did not undergo the procedure.

A multiple myeloma expert helps newly diagnosed patients understand the standard of care for their disease.

Patients with multiple myeloma have a lot to look forward to in the treatment space thanks to precision medicine, but one treatment option alone will not cure the disease.

New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.

At the 2019 CURE® Educated Patient® Summit on Multiple Myeloma patient advocate and 10-year survivor Terry White had the chance to share advice on handling a cancer diagnosis.

Naturally, newly diagnosed patients with multiple myeloma have a lot of questions for their physicians. Dr. Joshua Richter had the time to discuss some of them.

Patients with metastatic breast cancer who received an oral version of the chemotherapy drug experienced improved response rates and reductions in peripheral neuropathy compared to those who took the drug intravenously.

At the 2019 San Antonio Breast Cancer Symposium, Khevin Barnes advocated on behalf of men with breast cancer, but also advocated for more men with breast cancer to join him.

Patients with early-stage triple-negative breast cancer who did not have circulating tumor DNA in their blood experienced superior outcomes to chemotherapy followed by surgery.

Residual cancer burden can help physicians pinpoint accurate long-term predictions about the likelihood that a patient’s breast cancer will return.

At CURE’s Educated Patient Summit on Multiple Myeloma Dr. Shebli Atrash had the chance to further discuss with CURE what questions he addresses most when patients with multiple myeloma undergo diagnostic testing.

At CURE’s Educated Patient Summit on Multiple Myeloma, Dr. Barry Paul discussed the role of minimal residual disease measurement and how it may be used in the future to determine treatment options for patients with myeloma.

Dr. Cesar Rodriguez offers a message of hope and self-determination for patients with multiple myeloma.

Women who took estrogen alone as hormone therapy for their menopause experienced decreased rates of breast cancer and death from the disease even after they stopped taking the therapy, when compared to women who took estrogen with progestin.

Survival and recurrence rates were similar among patients with breast cancer who either received accelerated partial breast irradiation or whole breast irradiation.

This massive event for women with breast cancer just may be “man’s breast friend”.

Women treated with Arimidex for five years were 50% less likely to have developed breast cancer recurrence compared with women given placebo at nearly 11 years follow-up after stopping treatment.

Adding Tecentriq to chemotherapy before surgery did not improve the rate of pathologic complete response in patients with advanced, early-stage triple-negative breast cancer.

Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.

Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.

The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.

Expanding a combination from two drugs to three may lengthen the time until disease progression for patients with relapsed or refractory multiple myeloma.

Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.